Peng Jie, Chen Chunli, Zhang Hongtao, Zhang Lihua, Liu Jingjing, Ren Jianing, Zhao Peiquan
Department of Ophthalmology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Ophthalmology, Tianjin Medical University Eye Hospital, Tianjin, China.
Retina. 2021 Apr 1;41(4):726-734. doi: 10.1097/IAE.0000000000002922.
To report long-term surgical outcomes of autologous and allogenic lens capsular flap transplantation (LCFT) in refractory macular hole (MH) treatment.
Fifty consecutive eyes with refractory MH who received LCFT were reviewed retrospectively. Twelve eyes underwent autologous LCFT (LCF obtained from the same eye in 7 eyes and the fellow eye in 5 eyes) and 38 eyes with allogenic LCFT. All eyes underwent complete vitrectomy, internal limiting membrane peeling if not peeled, LCF transplantation, and 15% perfluoropropane tamponade. Simultaneous autologus whole-blood application was applied in 31 eyes to reduce LCF dislocation. The patients maintained a facedown position for 2 weeks postoperatively. Demographic information, functional results, and structural changes were evaluated.
The mean preoperative MH diameter was 1,102.00 µm ± 561.63 µm. The mean follow-up duration was 18.50 months ± 6.05 months (range, 12.0-38.9 months). The MH was completely closed in 48 eyes (96.00%) (18 eyes receiving autologous LCFT and 30 receiving allogenic LCFT). There are no differences of age, previous MH surgery times, MH diameter, preoperative and postoperative best-corrected visual acuity, and closure rate between the subgroups. The median visual acuity improved from 1.78 (interquartile range, 1.28-1.85) logarithm of the minimum angle of resolution (median Snellen acuity: 20/1,200) preoperatively to 1.00 (interquartile range, 0.90-1.70) logarithm of the minimum angle of resolution (median Snellen acuity: 20/200) (P < 0.01) in all patients.
Both autologous and allogenic LCFT application may provide anatomical and visual improvements in refractory MH cases. Blood application can be applied in selected cases to reduce LCF dislocation. LCFT can be performed as first-line treatment for refractory MHs.
报告自体和异体晶状体囊瓣移植(LCFT)治疗难治性黄斑裂孔(MH)的长期手术效果。
回顾性分析50例接受LCFT治疗的难治性MH患者的连续病例。12只眼接受自体LCFT(7只眼的晶状体囊瓣取自同一只眼,5只眼取自对侧眼),38只眼接受异体LCFT。所有患者均接受了完全玻璃体切除术,若未进行内界膜剥除则进行剥除,然后进行LCFT移植,并使用15%的全氟丙烷进行填塞。31只眼同时应用自体全血以减少LCFT移位。患者术后保持俯卧位2周。评估患者的人口统计学信息、功能结果和结构变化。
术前MH的平均直径为1,102.00 µm±561.63 µm。平均随访时间为18.50个月±6.05个月(范围为12.0 - 38.9个月)。48只眼(96.00%)的MH完全闭合(18只接受自体LCFT,30只接受异体LCFT)。各亚组之间在年龄、既往MH手术次数、MH直径、术前和术后最佳矫正视力以及闭合率方面无差异。所有患者的视力中位数从术前的1.78(四分位间距,1.28 - 1.85)最小分辨角对数(Snellen视力中位数:20/1,200)提高到1.00(四分位间距,0.90 - 1.70)最小分辨角对数(Snellen视力中位数:20/200)(P < 0.01)。
自体和异体LCFT应用均可为难治性MH病例带来解剖学和视力改善。在特定病例中应用血液可减少LCFT移位。LCFT可作为难治性MH的一线治疗方法。